Novo Nordisk’s New India Chief Steps Into Bustling Diabetes Arena
Novo Nordisk’s new India managing director takes charge amid heightened competition in the diabetes space. The Danish firm stays committed to bringing new products to this market at a faster clip and all eyes will be on the launch trajectory of therapies like semaglutide.
You may also be interested in...
Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?
Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.
And how in contrast, Novo Nordisk is launching its oral GLP-1 agonist for diabetes at a price that may set up 'business as usual' tensions with pharmacy benefit managers and payers.